Truist analyst David MacDonald raised the firm’s price target on CVS Health (CVS) to $76 from $60 and keeps a Buy rating on the shares after its Q4 earnings beat. The company’s FY25 guidance is a “strong starting point”, with several steps having been taken that should help drive improved Health Care Benefits margins and underpin its solid/improved performance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Target downgraded, Cisco upgraded: Wall Street’s top analyst calls
- CVS Health price target raised to $75 from $63 at BofA
- Optimistic Future for CVS Health: Strong Q4 2024 Performance and Promising 2025 Outlook
- CVS Health price target raised to $73 from $68 at Wells Fargo
- Positive Outlook and Attractive Valuation Drive Buy Rating for CVS Health